TYMLOS Drug Patent Profile

Which patents cover Tymlos, and what generic alternatives are available?

Tymlos is a drug marketed by Radius and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-six patent family members in twenty-nine countries.

The generic ingredient in TYMLOS is abaloparatide. One supplier is listed for this compound. Additional details are available on the abaloparatide profile page.

DrugPatentWatch^® Generic Entry Outlook for Tymlos

Tymlos was eligible for patent challenges on April 28, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 3, 2027. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TYMLOS

International Patents:	56
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	6
Drug Prices:	Drug price information for TYMLOS
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TYMLOS
What excipients (inactive ingredients) are in TYMLOS?	TYMLOS excipients list
DailyMed Link:	TYMLOS at DailyMed

See drug prices for TYMLOS

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TYMLOS

NDA:

208743

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TYMLOS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Affiliated Hospital of Qingdao University	PHASE1
University of Vermont	Phase 2
Crozer-Keystone Health System	Phase 4

See all TYMLOS clinical trials

Pharmacology for TYMLOS

Drug Class

Parathyroid Hormone-Related Peptide Analog

Paragraph IV (Patent) Challenges for TYMLOS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TYMLOS	Subcutaneous Injection	abaloparatide	3.12 mg/1.56 mL	208743	1	2022-06-21

US Patents and Regulatory Information for TYMLOS

TYMLOS is protected by twelve US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Radius	TYMLOS	abaloparatide	SOLUTION;SUBCUTANEOUS	208743-001	Apr 28, 2017		RX	Yes	Yes
Radius	TYMLOS	abaloparatide	SOLUTION;SUBCUTANEOUS	208743-001	Apr 28, 2017		RX	Yes	Yes
Radius	TYMLOS	abaloparatide	SOLUTION;SUBCUTANEOUS	208743-001	Apr 28, 2017		RX	Yes	Yes			Y

EU/EMA Drug Approvals for TYMLOS

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Radius Health Ireland Ltd	Eladynos	abaloparatide	EMEA/H/C/004157Treatment of osteoporosis.	Refused	no	no	no		2019-01-07
Theramex Ireland Limited	Eladynos	abaloparatide	EMEA/H/C/005928Treatment of osteoporosis in postmenopausal women at increased risk of fracture.	Authorised	no	no	no	2022-12-12

International Patents for TYMLOS

When does loss-of-exclusivity occur for TYMLOS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

France

Hong Kong

Israel

Japan

Lithuania

Luxembourg

Mexico

Netherlands

New Zealand

Norway

Poland

Portugal

Russian Federation

Serbia

Singapore

Slovenia

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TYMLOS around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2020207653
Brazil	112021011566
Canada	3122231

Supplementary Protection Certificates for TYMLOS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2073789	301235	Netherlands		PRODUCT NAME: ABALOPARATIDE; REGISTRATION NO/DATE: EU/1/22/1706 20221213
2073789	CA 2023 00019	Denmark		PRODUCT NAME: ABALOPARATID; REG. NO/DATE: EU/1/22/1706 20221213
2073789	2023C/523	Belgium		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), OTHER

TYMLOS (abaloparatide) market dynamics and financial trajectory: sales trends, payer dynamics, competition, and exclusivity-driven risk

Last updated: July 23, 2026

TYMLOS (abaloparatide) has been in a late-growth phase as managed care pressure rises and competition intensifies in osteoporosis. Price erosion, formulary tightening, and sequencing dynamics (including use of anabolic-first strategies followed by antiresorptives) have shaped revenue momentum. Financial trajectory is tied to (1) duration of coverage under key contracts, (2) substitution pressure from abaloparatide-adjacent anabolic and teriparatide bioscoped/brand and (3) clinician switching based on efficacy, dosing convenience, and perceived risk profiles.

Clinical context that drives market behavior TYMLOS is a daily, patient-administered anabolic agent used to treat osteoporosis in postmenopausal women at high risk for fracture and in men at high risk for fracture who are at high risk for osteoporotic fracture (label details vary by region, with US being the primary driver for FDA-related exclusivity analysis). Its commercial profile depends on adherence and persistence with the 2-year lifetime exposure limit and on payer rules around prior authorization, step edits, and documentation of fracture risk.

---

How have TYMLOS sales performed and what is the revenue trajectory?

Bottom-line trajectory

• TYMLOS has shown growth followed by deceleration as the anabolic class matured and as coverage became more conditional.
• Revenue is most sensitive to (a) the rate of new starts (patients switching from antiresorptives to anabolic-first), (b) loss of protected formulary positions, and (c) shifts in market share toward competitors in managed care formularies.

What moves TYMLOS revenue period-to-period

• Coverage wins/losses: Health plans change coverage designs quickly after PBM formulary cycles. TYMLOS revenue responds with lagged starts and reduced persistence.
• Utilization constraints: The 24-month cumulative dosing cap limits lifetime revenue per patient.
• Adherence and switching: Real-world under-dosing or discontinuation reduces throughput from “eligible” to “treated.”
• Payer scrutiny: Prior authorization criteria tightening around T-scores, fragility fracture history, glucocorticoid exposure, and documented failure/intolerance of antiresorptives can reduce eligible starts.

Key metrics buyers track

• New prescriptions per 90 days by channel (retail, specialty).
• Script conversion at copay assistance utilization points.
• Days supply and refill persistence after initial 30/60/90-day ramp.
• Share-of-voice changes around seasonal prescribing peaks (new deductibles and Q1 formulary changes can drive step-up or step-down).

---

What market dynamics are pressuring TYMLOS: pricing, payers, and utilization management?

1) Managed care and formulary tightening TYMLOS is subject to plan-specific rules that can include:

• Step therapy requiring antiresorptive exposure before anabolic coverage in non-very-high-risk patients.
• Higher PA burdens in patients without documented vertebral or hip fracture risk.
• Brand-only coverage in some formularies but restricted by criteria.

2) Competitive sequencing in osteoporosis Real-world care often follows a sequencing model:

• Anabolic-first for very-high-risk patients (fractures despite antiresorptives, very low T-scores, multiple vertebral fractures).
• Transition to antiresorptives (denosumab or bisphosphonates) to maintain gains.

That means TYMLOS faces revenue sensitivity to clinical guidelines adoption and payer-provided pathways that define who qualifies as “very high risk.”

3) Net price compression Brand net pricing is pressured by:

• PBM contracting and rebate structures.
• Competitor reference pricing or class-based pricing strategies.
• Copay assistance influence when applicable, which can shift gross-to-net dynamics and patient access.

---

Which competitors most affect TYMLOS market share and pricing?

Competitive set TYMLOS competes across anabolic and adjacent therapeutic options used for similar populations:

• Other anabolic osteoporosis agents (class-level competition).
• Teriparatide (including delivery-system variants where covered).
• Denosumab and bisphosphonates as sequencing and substitution options when anabolic access is restricted.

How substitution risk differs by patient risk tier

• Very-high-risk patients: Lower substitution likelihood because clinicians seek fastest fracture-risk reduction and anabolic benefit.
• High-risk but borderline coverage criteria: Higher substitution risk when PA criteria tighten.

Payer logic that tends to shift share

• Plans may steer patients toward lower-cost anabolic options or require more documentation.
• When competitors have stronger formulary placement, TYMLOS faces reduced new starts and increased switching.

---

What is the FDA and Orange Book exclusivity status for TYMLOS?

Orange Book relevance TYMLOS availability in the US depends on both patent coverage (listed for the drug product and related methods) and exclusivity protections tied to FDA approval. As those protections near expiry, the market typically shifts toward generic entry risk and lower net pricing.

Commercial implication

• As exclusivity and key patents near expiry, contracting pressure increases even before a generic is launched because payers negotiate for price-down scenarios.
• The market also rebalances around anticipated launch timing through channel stocking decisions and anticipated substitution.

---

When does TYMLOS lose exclusivity and what generic entry risks exist?

Generic entry risk profile Generic risk is driven by:

• Patent expirations covering active ingredient and drug product composition.
• Method-of-use patents tied to specific populations or dosing regimens.
• Formulation and device-related IP (injector-related protections can matter if they constrain generic usability).

Paragraph IV and settlement dynamics (typical pattern) If any generic applicant filed an Abbreviated New Drug Application with a Paragraph IV certification, the pathway usually includes:

• Litigation by the brand against the generic’s certifications.
• Possible settlement leading to delayed launch.
• Adoption of “design-around” formulations that may still face manufacturing or device-related barriers.

Market impact before launch Even without generic approval, exclusivity timelines can:

• Trigger PBM formulary changes.
• Increase utilization controls and brand switching.
• Cause higher rebate pressure as buyers negotiate down in anticipation of competition.

---

What patents protect TYMLOS and how strong is the patent estate?

Patent estate strength drivers The practical strength of a TYMLOS patent portfolio depends on whether key claims cover:

• Drug substance and drug product composition.
• Device, injection system, and delivery system features.
• Method-of-use and dosing regimen claims that are implicated by label indications.
• Manufacturing process claims that constrain generic manufacturing.

How estate strength translates into business outcomes

• Strong composition claims delay true “on-label generic substitution.”
• Method-of-use coverage can delay generic competitive impact even if a product is approved, because substitution depends on whether prescribers and plans follow label-level claims.
• Device or formulation IP can restrict “AB-rated” substitution or drive more complex launch tactics.

---

What formulation and device IP issues affect TYMLOS generic or biosimilar substitution?

Device and usability Injectable biologically active peptide drugs rely on delivery systems. If patents cover:

• Needle/injection mechanics,
• Pen structure,
• Release kinetics or usability, then “launch by AB substitution” can be delayed or restricted.

Formulation constraints For peptide injectables, IP can also focus on:

• Stabilizers, buffers, and lyophilization or solution formulation parameters.
• Shelf-life, handling, and reconstitution properties.

These can affect generic feasibility and time-to-market.

---

What is the current litigation landscape affecting TYMLOS market access?

Litigation categories that matter

• Patent infringement suits by the brand involving ANDA/Paragraph IV challenges.
• Disputes over claim construction (device/formulation/method claims).
• Settlements affecting launch dates or permissible product features.

Business impact

• Pending litigation tends to delay generic entry.
• Settlements (if any) can create a clear “launch window” that payers incorporate into contracting decisions.

---

How does TYMLOS compare with other osteoporosis therapies on payer coverage and sequencing?

Coverage determinants Payer coverage and clinical adoption depend on:

• Patient risk stratification criteria in PA forms.
• Evidence thresholds for very-high-risk designation.
• Expected persistence given dosing frequency and injection training needs.

Sequencing economics In anabolic-first pathways, the economic burden sits on the first agent, then maintenance therapy. If a competitor offers better access or preferred formulary placement, TYMLOS loses share even when clinical outcomes are similar, because payer pathways influence clinician selection.

---

What commercial channel mix drives TYMLOS performance?

Channel dynamics

• Retail tends to be more sensitive to copay design and deductible cycles.
• Specialty distribution and patient support programs can stabilize access and drive persistence.
• PBM-driven net pricing and coverage tiers shape patient throughput.

Persistence and lifetime value Because TYMLOS is constrained by a lifetime exposure limit, revenue is a function of:

• How many patients reach the full treatment course, and
• How well the maintenance plan keeps patients on recommended downstream therapy (which affects clinicians’ willingness to keep the initial anabolic in the pathway).

---

What is the likely next 12–36 month outlook for TYMLOS revenues?

Base-case trajectory

• Continuing revenue pressure from formulary tightening and competitive dynamics is likely.
• Upside exists if payer pathways define anabolic-first access more broadly and if clinician switching remains limited.
• Downside risk increases near exclusivity/patent expiry dates.

What to watch for

• PBM formulary announcements and plan-specific PA updates.
• Changes in net pricing tied to rebate renegotiations.
• Signals from generic litigation filings and any settlement terms that set launch timing.
• Prescription trends in very-high-risk subsegments, where anabolic access is most likely.

---

Key Takeaways

• TYMLOS revenue performance is primarily driven by managed care access, patient eligibility for anabolic-first pathways, and persistence under the 24-month exposure cap.
• The anabolic osteoporosis market is increasingly shaped by payer restrictions and contracting, which can accelerate net price compression even before generic entry.
• Exclusivity and patent timelines determine the magnitude of future pricing pressure and generic substitution risk.
• The competitive outcome depends on formulary positioning and pathway rules more than on aggregate clinical differentiation alone.

---

FAQs

What payer rules most determine TYMLOS patient access?

Prior authorization criteria tied to fracture history, T-score thresholds, and prior antiresorptive exposure are the main gatekeepers.

How does TYMLOS dosing duration limit lifetime sales per patient?

The 24-month lifetime exposure constraint reduces the maximum revenue opportunity per treated patient and raises the importance of new starts.

Do settlements or Paragraph IV challenges affect TYMLOS contract negotiations before generic launch?

Yes. Even before approval, known launch dates and litigation outcomes drive PBM and payer expectations and can increase rebate pressure.

What is the impact of switching from TYMLOS to denosumab or bisphosphonates?

Switching affects revenue timing and sequencing economics; maintaining downstream antiresorptive therapy can preserve overall “anabolic-first” pathway adherence and influence future anabolic selection.

How do formulary placements change TYMLOS prescriptions most quickly?

Formulary and PA policy changes affect new starts within subsequent prescribing cycles, with persistence impacts showing over the next refill periods.

---

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-07-23).
2. U.S. Food and Drug Administration. TYMLOS (abaloparatide) Prescribing Information. (Accessed 2026-07-23).
3. U.S. Patent and Trademark Office / FDA. Patent and exclusivity information for FDA-approved drug products (Orange Book listings and associated regulatory exclusivities). (Accessed 2026-07-23).

DrugChatter Q&A for TYMLOS

When was tymlos fda approved?
Tymlos specialty pharmacy?
Does tymlos have a generic?
Tymlos patient assistance application?
How much does tymlos cost?